Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3300557rdf:typepubmed:Citationlld:pubmed
pubmed-article:3300557lifeskim:mentionsumls-concept:C0376544lld:lifeskim
pubmed-article:3300557lifeskim:mentionsumls-concept:C0011900lld:lifeskim
pubmed-article:3300557lifeskim:mentionsumls-concept:C2745888lld:lifeskim
pubmed-article:3300557lifeskim:mentionsumls-concept:C0205473lld:lifeskim
pubmed-article:3300557pubmed:issue6 Pt 2lld:pubmed
pubmed-article:3300557pubmed:dateCreated1987-7-27lld:pubmed
pubmed-article:3300557pubmed:abstractTextThe analysis of cell surface markers with monoclonal antibodies has recently been developed and has been proved to be valuable in the diagnosis and classification of hematopoietic tumors. Occasionally, however, such serological studies have been shown to be inconclusive in identifying cell lineage and or clonal proliferation. In order to overcome these problems, two new approaches were introduced in our laboratory. First, T cell receptor and immunoglobulin gene rearrangement analysis as a means of immunomolecular marking was carried out. Second, a double immunoenzymatic staining technique for determining the surface phenotypes of proliferating lymphocytes using a monoclonal antibody against DNA polymerase alpha together with those detecting lymphocyte membrane antigens was developed. The results revealed by these techniques strongly suggested that some CD2-, CD5+, CD7+ ALL cases are of T cell origin and that AILD may be a neoplastic disease derived from either of the subsets of peripheral T cells.lld:pubmed
pubmed-article:3300557pubmed:languagejpnlld:pubmed
pubmed-article:3300557pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3300557pubmed:citationSubsetIMlld:pubmed
pubmed-article:3300557pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3300557pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3300557pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3300557pubmed:statusMEDLINElld:pubmed
pubmed-article:3300557pubmed:monthJunlld:pubmed
pubmed-article:3300557pubmed:issn0385-0684lld:pubmed
pubmed-article:3300557pubmed:authorpubmed-author:TakahashiTTlld:pubmed
pubmed-article:3300557pubmed:authorpubmed-author:UedaRRlld:pubmed
pubmed-article:3300557pubmed:authorpubmed-author:ObataYYlld:pubmed
pubmed-article:3300557pubmed:issnTypePrintlld:pubmed
pubmed-article:3300557pubmed:volume14lld:pubmed
pubmed-article:3300557pubmed:ownerNLMlld:pubmed
pubmed-article:3300557pubmed:authorsCompleteYlld:pubmed
pubmed-article:3300557pubmed:pagination2176-84lld:pubmed
pubmed-article:3300557pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:3300557pubmed:meshHeadingpubmed-meshheading:3300557-...lld:pubmed
pubmed-article:3300557pubmed:meshHeadingpubmed-meshheading:3300557-...lld:pubmed
pubmed-article:3300557pubmed:meshHeadingpubmed-meshheading:3300557-...lld:pubmed
pubmed-article:3300557pubmed:meshHeadingpubmed-meshheading:3300557-...lld:pubmed
pubmed-article:3300557pubmed:meshHeadingpubmed-meshheading:3300557-...lld:pubmed
pubmed-article:3300557pubmed:meshHeadingpubmed-meshheading:3300557-...lld:pubmed
pubmed-article:3300557pubmed:meshHeadingpubmed-meshheading:3300557-...lld:pubmed
pubmed-article:3300557pubmed:meshHeadingpubmed-meshheading:3300557-...lld:pubmed
pubmed-article:3300557pubmed:meshHeadingpubmed-meshheading:3300557-...lld:pubmed
pubmed-article:3300557pubmed:meshHeadingpubmed-meshheading:3300557-...lld:pubmed
pubmed-article:3300557pubmed:year1987lld:pubmed
pubmed-article:3300557pubmed:articleTitle[Serological and immunomolecular markers for the diagnosis of hematopoietic tumors].lld:pubmed
pubmed-article:3300557pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3300557pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:3300557pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed